BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
98.08
0.00 (0.00%)
At close: Sep 26, 2025, 4:00 PM EDT
98.31
+0.23 (0.23%)
After-hours: Sep 26, 2025, 4:57 PM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 260.80M EUR in the quarter ending June 30, 2025, with 102.64% growth. This brings the company's revenue in the last twelve months to 2.88B, up 6.98% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.88B EUR
Revenue Growth
+6.98%
P/S Ratio
6.98
Revenue / Employee
425,044 EUR
Employees
6,772
Market Cap
23.58B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BNTX News
- 3 days ago - BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025 - GlobeNewsWire
- 14 days ago - COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says - Market Watch
- 18 days ago - BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
- 18 days ago - BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
- 18 days ago - First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - GlobeNewsWire
- 18 days ago - Pfizer, partner BioNTech say updated COVID shot shows better immune response - Reuters
- 18 days ago - Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula - Business Wire
- 21 days ago - BioNTech, Duality score initial trial win with breast cancer precision drug - Reuters